

LBEBW

Bereit für Neues

Aktie Kompakt

LBBW Research | Corporates

USU

- Targets for 2020 exceeded
- · Guidance for 2021 more than cautious
- · Price target and rating confirmed

The sales and earnings results achieved by USU in 2020 came as a positive surprise to us. This growth was mainly driven by the Consulting segment, which benefited from strong business with the public sector in Germany and with financial service providers.

- Newly filled management positions in sales and marketing in Germany, France and the US and strong staff growth in sales are increasingly generating new orders.
- USU more than compensated for the negative margin effect of the progressive changeover from licenses to SaaS in product business.
- The record order backlog is an encouraging sign for 2021, but USU is keeping things low-key with its cautious guidance. Despite the continuing economic headwind due to COVID-19, at least in the first half of 2021, our planning is more optimistic.
- The medium-term targets of average organic sales growth of 10% for the coming years and growth in the operating margin on an adjusted EBIT basis to 13–15% by 2024 have been confirmed.
- We are retaining our price target, which is based on a DCF valuation, at EUR 32.50 and confirming our Buy recommendation.

Opportunities

Multi-award-winning software applications

Big data and digitalization of companies driving growth

International expansion, sound balance sheet ratios

Threats

Strong SaaS growth holding back margin development

Individual larger orders could create more volatility over the year

Low free float market capitalization

This document is a translation of the financial analysis: USU, original publication date: 2021-03-25. The translation has been made for convenience only with the german original always prevailing in all respects, especially in case of potential discrepancies resulting from the translation. , **RATING BUY** (UNCHANGED)

TARGET PRICE 32.50 EUR (UNCHANGED)



Reuters: OSPGk	Bloomberg: OSP2 GY
CURRENT PRICE	28.00 EUR
(XETRA; 2021-03-25;	02:57 PM)
CLOSE PRICE (2021-	03-24) 27.00 EUR
EXPECTED PERFOR	MANCE 20.4 %
MARKET CAPITALIZA	TION 284 m EUR
INDEX (WEIGHT)	CDAX (0.01 %)
ISIN / WKN	DE000A0BVU28 / A0BVU2
SECTOR	Software

Key figures

Company figures in m EUR, per share data in EUR

2020 2021E 2022E Sales 107 115 128 EBIT adjusted 9 11 15 EPS adjusted 0.72 0.74 0.99 Dividend 0.40 0.45 0.50 P / E adjusted 38.3 36.3 27.3 Dividend yield 1.4 % 1.7 % 1.9 %	per share uata in EUr	`		
EBIT adjusted 9 11 15 EPS adjusted 0.72 0.74 0.99 Dividend 0.40 0.45 0.50 P / E adjusted 38.3 36.3 27.3		2020	2021E	2022E
EPS adjusted 0.72 0.74 0.99 Dividend 0.40 0.45 0.50 P / E adjusted 38.3 36.3 27.3	Sales	107	115	128
Dividend 0.40 0.45 0.50 P / E adjusted 38.3 36.3 27.3	EBIT adjusted	9	11	15
P / E adjusted 38.3 36.3 27.3	EPS adjusted	0.72	0.74	0.99
	Dividend	0.40	0.45	0.50
Dividend yield 1.4 % 1.7 % 1.9 %	P / E adjusted	38.3	36.3	27.3
	Dividend yield	1.4 %	1.7 %	1.9 %

Source: USU, Refinitiv, LBBW Research

Analyst: Mirko Maier Senior Investment Analyst

COMPLETION: 2021-04-08 16:03 FIRST DISSEMINATION: 2021-04-08 16:05

Company profile.

USU is the largest European provider of IT and knowledge management software. The company develops applications for recording IT infrastructure in terms of performance, spread and cost. In addition, knowledge-based KM solutions are developed. The product portfolio is rounded out by accompanying services. In 2020, USU had 732 employees and generated sales of EUR 107m. The balance sheet is characterized by a high equity ratio, no liabilities to banks and high net liquidity. Founder Udo Strehl is the majority owner of the company with a share of just over 50%.

Business Update.

Targets for 2020 achieved: In view of the pandemic, USU had temporarily no longer expected to be able to achieve its annual targets for sales (EUR 102–107m) and earnings (EUR 7–10m) that were issued at the beginning of 2021. But with the consolidated sales of EUR 107.3m and the operating earnings of EUR 9.2m now achieved, USU delivered a positive surprise. This growth was mainly driven by the Consulting segment, which benefited from strong business with the public sector in Germany and with financial service providers. The operating margin climbed from 6.5% to 8.6%. USU thus more than compensated for the negative margin effect of the progressive changeover from licenses to SaaS in product business.

Guidance for 2021 more than cautious: In the coronavirus year 2020, USU increased its sales by a substantial 12.2% while its order backlog grew by 26% to a record level of EUR 62m. Nonetheless, USU only expects to achieve slight, single-digit sales growth due to COVID-19. Operating earnings are expected to remain at the previous year's level or, in the best-case scenario, increase to EUR 10m. Despite the continuing economic headwind due to COVID-19, at least in the first half of 2021, we anticipate sales growth of almost 7% and a rise in adjusted EBIT to just under EUR 11m. The medium-term targets of average organic sales growth of 10% for the coming years and growth in the operating margin on an adjusted EBIT basis to 13–15% by 2024 have been confirmed.



12,2%

Sales growth in 2020

Next Events:

Quarterly report 2021-05-14



Price performance and shareholder structure.

Udo Strehl (51.18%)
MainFirst SICAV (5.05%)
Peter Scheufler (4.97%)

Freefloat

38.80%

Source: USU, Refinitiv, LBBW Research

Key data.

(Company figures in m EUR, per share data in EUR)


	2016	2017	2018	2019	2020	2021E	2022E
PROFIT AND LOSS STATEMENT	(DEC 31)						
Sales	72	84	90	96	107	115	128
EBIT	8	3	3	4	7	9	12
EBIT adjusted	10	6	4	6	9	11	15
Earnings before taxes (EBT)	8	3	3	4	7	9	12
Net profit	7	3	1	5	5	6	9
EPS adjusted	0.75	0.58	0.18	0.70	0.72	0.74	0.99
Dividend	0.40	0.40	0.40	0.40	0.40	0.45	0.50
GROWTH YOY							
Sales	n.a.	17.0 %	7.3 %	5.7 %	12.2 %	6.8 %	11.5 %
EBIT	n.a.	-61.2 %	-16.0 %	49.8 %	73.2 %	24.6 %	42.9 %
EBIT adjusted	n.a.	-36.3 %	-32.7 %	50.9 %	48.5 %	17.5 %	33.6 %
Earnings before taxes (EBT)	n.a.	-62.5 %	-9.7 %	44.1 %	67.9 %	28.0 %	43.1 %
EPS adjusted	n.a.	-22.5 %	-68.4 %	281.7 %	3.6 %	3.0 %	33.2 %
Dividend	n.a.	0.0 %	0.0 %	0.0 %	0.0 %	12.5 %	11.1 %
MARGINS							
EBITDA margin	15.0 %	8.1 %	6.1 %	10.4 %	11.5 %	12.3 %	14.1 %
EBIT margin	13.3 %	7.3 %	4.6 %	6.5 %	8.6 %	9.5 %	11.3 %
Earnings before taxes (EBT)	11.5 %	3.7 %	3.1 %	4.2 %	6.3 %	7.6 %	9.7 %
Net profit margin	9.4 %	4.0 %	1.1 %	5.5 %	5.1 %	5.5 %	7.0 %
VALUATION RATIOS							
Enterprise value / Revenue	2.6	3.1	1.7	1.6	2.6	2.3	2.1
Enterprise value / EBITDA	17.7	38.0	28.5	15.6	22.1	18.8	14.7
Enterprise value / EBIT	19.8	42.4	38.1	24.8	29.6	24.3	18.2
Price-To-Earnings ratio (P / E ratio)	27.1	45.3	86.2	22.7	38.3	36.3	27.3
Price-To-Book ratio (P / B ratio)	3.3	4.4	2.8	2.8	4.7	4.5	4.2
Dividend yield	2.0 %	1.5 %	2.5 %	2.5 %	1.4 %	1.7 %	1.9 %

Source: USU, Refinitiv, LBBW Research





Valuation.



Disclaimer.



LBBW Research Rating Systematics (absolute share rating system)

Rating definitions: Buy: Based on a time horizon up to 12 months, we recommend that investors buy the stock.

Sell: Based on a time horizon up to 12 months, we recommend that investors sell the stock

Hold: We take a neutral view on the stock and, based on a time horizon of up to 12 months, do not recommend either a Buy or Sell.

Under review: The rating is currently updated. Suspended: The evaluation of the company is currently not feasible.

This report is addressed exclusively at recipients in the EU. Switzerland and Liechtenstein.

This report is not being distributed by LBBW to any person in the United States and LBBW does not intend to solicit any person in the United States.

LBBW is under the supervision of the European Central Bank (ECB), Sonnemannstraße 22, 60314 Frankfurt/Main (Germany) and the German Federal Financial Supervisory Authority (BaFin), Graurheindorfer Str. 108, 53117 Bonn (Germany) / Marie-Curie-Str. 24-28, 60439 Frankfurt/Main (Germany).

LBBW has taken measures to ensure that conflicts of interest are avoided as far as possible or are treated appropriately with regard to the production and distribution of financial analyses. These measures include in particular:
- Chinese walls blocking access by employees who draft financial analyses to information that could create conflicts of interest on the part of LBBW vis-à-vis the issuers

- a ban on own-account trading in securities for which or for the issuers of which the employees concerned write financial analyses, and the ongoing monitoring of

compliance with statutory requirements by employees in the Compliance unit.

This report is distributed for your private information subject to express acknowledgement on the part of the recipient that it does not constitute a recommendation or call to buy, hold or sell securities and that it does not constitute a medium by which a corresponding financial instrument is offered or sold. It is produced regardless of your own investment objectives, your financial situation or your special requirements. Any reproduction of this information material in part or in its entirety is prohibited and you may only pass this material on to your adviser or the professionals who assist you in the valuation of financial instruments.

This information is intended exclusively for information purposes and is not intended to constitute a reliable basis for reaching decisions as to whether to invest in this particular financial instrument. Potential investors should base their decisions on information that is contained in the issuing prospectus and other publicly available information.

LBBW has drawn the information contained in this report from sources that it deems to be reliable. However, LBBW is not in a position to verify such information and because of the possibility of human and technical error on the part of our sources, LBBW or others it is not claimed that the information in this report is correct or complete in all important points. LBBW excludes any liability with regard to the accuracy, appropriateness or completeness of all information and because of the sources, to the statements or or missions or the result of making use of this information. The statements made in this report are statements of opinion and do not claim to be statements of fact or recommendations to buy, hold or sell a financial instrument. Any changes to a rating may have major repercussions on stock performance. Information on past performance does not indicate future performance. LBBW may have published other reports in the past and may publish further reports in the future that do not correspond with the information in this report and which draw different conclusions. These reports are flect the various assumptions, views and analytical methods adopted by the analysts that have drafted them and LBBW is in no way obliged to ensure that such further reports are brought to the attention of a recipient of this report. This material does not claim to be comprehensive nor does it contain all information that a potential investor may seek to obtain.

Nothing in this report constitutes advice of an investment, legal, accounting or tax nature. Nor does anything in this report claim that a certain investment or strategy corresponds to your own individual circumstances or is suitable for them or otherwise constitutes a personal recommendation to you. This report is directed exclusively at and is only intended for persons who are adequately qualified to understand the risks involved. This publication cannot replace individual advice. Before you make an investment decision, you should consult your independent investment consultant regarding further and more up-to-date information on special investment opportunities and for personal investment advice with regard to the appropriateness of investment in a financial instrument or the adoption of an investment strategy put forward in this report. This publication cannot replace individual advice.

Nothing that is stated by LBBW may be construed as meaning that there will be a secondary market for these financial instruments either now or at any time in the future. Investors should be able and also intend to hold such financial instruments indefinitely. A potential investor must determine whether the purchase of the financial instruments serves his financial requirements, objectives and situation and corresponds fully with all applicable guidelines and restrictions and whether the investment is appropriate and suitable regardless of the clear and high risks associated with investment in financial instruments. The information included in this report contains what are in some cases highly hypothetical analyses. This report is based on certain assumptions with respect to future events and conditions that are per se unsure, unpredictable and subject to change. No statement is made regarding the actual performance of the transaction and investors should not rely on the reports drawing attention to the actual performance of the transaction. Actual results will differ perhaps substantially from those in the report. Investors should view the reports in the light of these observations made in them. An investment in this particular financial instrument entails certain specific risks. Potential investors in this specific financial instrument should verify the information included in the preliminary issuing prospectus with care, including the section entitled "Risk Factors".

The specific financial instrument to which reference is made within this document may entail significant risks, including capital, interest-rate, index, currency, credit, political, liquidity, market-value, product and market risks, and may not be suitable for all investors. The financial instruments may experience sudden and major losses in value that cause losses that correspond to the original volume of investment when the investment is cashed in. Every transaction exercised is based exclusively on your appraisal of the financial, suitability and risk criteria. Under such circumstances LBBW lays no claim to act in an advisory capacity, nor are its employees authorized to do so.

Information on the recommendations is updated at least once a year.

We retain the right to change the opinions expressed herein at any time and without prior notice. Furthermore, we reserve the right to stop updating this information or to discontinue it fully without prior notice.

Additional required disclosures and overviews in accordance with Commission Delegated Regulation (EU) 2016/958 (especially Article 4 (1) e) and i) as well as Article 6 (3)) can be found at https://www.lbbw-research.de/publicdisclaimer-en.

The acceptance of provided research services by a securities services company can qualify as a benefit in supervisory law terms. In these cases LBBW assumes that the benefit is intended to improve the quality of the relevant service for the customer of the benefit recipient.

Please note that

- LBBW or an associated enterprise of LBBW supports the company in the market by entering buy or sell orders

- LBBW or an associated enterprise of LBBW has made an agreement on the production of financial analyses relating to the issuer or its financial instruments.

Date	Recommendation	Date	Target price
2020-05-27	Buy	2021-02-18	32.50 EUR
2017-01-09	Buy	2020-09-17	26.75 EUR
		2020-05-27	20.50 EUR
		2020-03-30	16.50 EUR
		2020-03-09	18.50 EUR